Mizuho raised the firm’s price target on Edwards Lifesciences (EW) to $87 from $85 and keeps an Outperform rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $81 from $75 at Morgan Stanley
- Cautious Outlook for Edwards Lifesciences Amidst TAVR Sales Challenges and Market Share Concerns
- Edwards Lifesciences’ PROGRESS Trial: A Game-Changer for Aortic Stenosis Treatment?
- Edwards Lifesciences Launches MITRIS Valve Study in China: A Potential Market Game-Changer
- Edwards Lifesciences initiated with a Buy at Argus